Igenomix USA, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Igenomix USA, LLC - overview
Established
1996
Location
Miami, FL, US
Primary Industry
Biotechnology
About
Based in Florida, US, and founded in 1996, Igenomix USA, LLC, operates as a healthcare company that provides genetic testing services for fertility problems. In March 2019, EQT, along with the company's management, agreed to acquire a majority stake in Igenomix S. L. from Charme Capital Partners, Amadeus Capital Partners, and Aleph Capital for USD 450 million.
In July 2021, Vitrolife AB, a portfolio company of Bure and EQT, agreed to fully acquire Igenomix S. L. from Charme Capital Partners and EQT for EUR 1. 25 billion.
The company was founded by Carlos Simón, and its current CEO is David Jimenez. Igenomix offers research and genetic testing services for reproductive health clinics. The company's services include CGT (carrier genetic test), reproductive genetics, and specializes in NACE (non-invasive prenatal test), ERA (endometrial receptivity array), PGD (preimplantation genetic diagnosis), and developing tools for the reproductive health field.
Current Investors
Vitrolife AB
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Epidemiology
Website
www.igenomix.com/
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Igenomix USA, LLC - financials
| Fiscal Year Ended | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Jun 30, 2019 | Jun 30, 2020 | Jun 30, 2021 |
|---|---|---|---|---|---|---|---|
| Revenue (USD) | 14,307,038.8 | 17,638,322.1 | 21,555,767.6 | 23,041,789.2 | - | - | - |
| % Revenue Growth (YoY) | - | 23.3% | 22.2% | 6.9% | - | - | - |
| EBITDA (USD) | 2,883,120.5 | 3,732,701.9 | 3,504,075.4 | (11,869,366.7) | - | - | - |
| Operating Income (USD) | 2,517,753.4 | 3,289,905.1 | 2,845,883.2 | (12,635,531.8) | - | - | - |
| Operating Margin | 17.6% | 18.7% | 13.2% | (54.8%) | - | - | - |
| % EBITDA Margin | 20.2% | 21.2% | 16.3% | (51.5%) | - | - | - |
| NET Income (USD) | 2,068,757.3 | 3,867,085.4 | 2,409,445.6 | (14,959,561.3) | - | - | - |
| % Net Margin | 14.5% | 21.9% | 11.2% | (64.9%) | - | - | - |
Igenomix USA, LLC - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | Igenomix USA, LLC | - | ||||||||
| Add-on | Completed | Igenomix USA, LLC | - | ||||||||
| Add-on, Trade Sale | Completed | Access Genomics | - | ||||||||
| Secondary Buyout | Completed | Igenomix USA, LLC | - | ||||||||
| Buyout | Completed | Igenomix USA, LLC | - |
Displaying 1 - 5 of 5
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.